Patterson Companies (PDCO) Q4 Earnings Beat, Revenues Up Y/Y
Patterson Companies, Inc. PDCO reported adjusted earnings per share (EPS) of 71 cents in fourth-quarter fiscal 2022, which surpassed the Zacks Consensus Estimate of 56 cents by 26.8%. The bottom line increased a significant 86.8% from the prior-year quarter.
GAAP EPS in the quarter was 65 cents, up 116.7% from the prior-year quarter.
For fiscal 2022, the company reported adjusted EPS of $2.27, up 18.8%. The figure outpaced the consensus mark by 7.1%.
Revenue Details
Net sales in the quarter were $1.64 billion, which lagged the Zacks Consensus Estimate by 1.7%. The top line, however, improved 4.9% year over year.
For fiscal 2022, revenues were $6.49 billion, up 9.9% from the prior fiscal year. The figure beat the consensus mark by 0.3%.
Segmental Analysis
The company currently distributes products through subsidiaries — Patterson Dental and Patterson Animal Health.
Dental Segment
This segment provides a complete range of consumable dental products, equipment, software, turnkey digital solutions and value-added services to dentists and laboratories throughout North America.
In the fiscal fourth quarter, dental sales increased 3.3% year over year to $636.4 million.
Dental Consumable
Sales in the sub-segment totaled $354.3 million, down 0.8% year over year.
Patterson Companies, Inc. Price, Consensus and EPS Surprise
Patterson Companies, Inc. price-consensus-eps-surprise-chart | Patterson Companies, Inc. Quote
Dental Equipment & Software
Sales in the segment rose 14.2% on a year-over-year basis to $208.4 million.
Value-added Services and Other
This segment comprises technical service, parts and labor, software support services and office supplies. Sales at the segment fell 3.2% on a year-over-year basis to $73.8 million.
Animal Health Segment
This segment is a leading distributor of veterinary supplies to clinics, public and private institutions and shelters across the United States.
In the fiscal fourth quarter, the segment sales increased 7.3% on a year-over-year basis to $1.01 billion.
Corporate
Sales at the segment were ($5.5) million, against $6.4 million in the year-ago quarter.
Margin Analysis
Gross profit in the reported quarter was $348.2 million, up 14.4% year over year. As a percentage of revenues, gross margin of 21.2% expanded 170 basis points (bps) on a year-over-year basis.
Operating expenses in the reported quarter amounted to $275.4 million, up 3.1% from the prior-year quarter.
The company reported an operating income of $72.8 million, surging 95% from the year-ago quarter. As a percentage of revenues, operating margin of 4.4% expanded 200 bps on a year-over-year basis.
Financial Position
The company exited the fiscal fourth quarter with cash and cash equivalents of $142 million, compared with $165 million on a sequential basis.
Cumulative net cash used in operating activities at the end of the fiscal fourth quarter was $980.9 million, noticeably wider than the year-ago quarter’s net cash utilized in operating activities of $730.5 million.
Fiscal 2023 Earnings Outlook
Patterson Companies issued its earnings outlook for fiscal 2023. The company projects adjusted EPS in the range of $2.25 to $2.35. The Zacks Consensus Estimate for the same is pegged at $2.25 per share.
Our Take
Patterson Companies ended fourth-quarter fiscal 2022 on a strong note, wherein both earnings and revenues beat the consensus mark. The company witnessed a solid performance in the Animal Health segment in the quarter under review. Apart from Dental Consumable, the Dental business showed improvement. A prudent cost savings approach and solid sales execution worked in favor of the stock. Sustained momentum in the Animal Health business and the company’s solid position in the market got reflected in the fiscal fourth-quarter results. A solid earnings outlook for fiscal 2023 is encouraging. Expansion in both gross and operating margins bodes well.
A broad spectrum of products cushions the company against economic downturns in the MedTech space. We believe that a diverse product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are key catalysts.
However, a rise in operating expenses remains a concern. Weakness in the Corporate segment is disappointing.
Zacks Rank
Patterson Companies carries a Zacks Rank #4 (Sell).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space that have announced quarterly results are UnitedHealth Group Incorporated UNH, AMN Healthcare Services, Inc. AMN and Masimo Corporation MASI.
UnitedHealth Group, carrying a Zacks Rank #2 (Buy), reported first-quarter 2022 adjusted EPS of $5.49, which beat the Zacks Consensus Estimate by 1.7%. Revenues of $80.1 billion outpaced the consensus mark by 1.9%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
UnitedHealth has an estimated long-term growth rate of 14.8%. UNH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%.
AMN Healthcare, sporting a Zacks Rank #1, reported first-quarter 2022 adjusted EPS of $3.49, which beat the Zacks Consensus Estimate by 7.4%. Revenues of $1.55 billion outpaced the consensus mark by 3.7%.
AMN Healthcare has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 15.6%.
Masimo reported first-quarter 2022 adjusted EPS of 93 cents, which surpassed the Zacks Consensus Estimate by 1.1%. Revenues of $304.2 million outpaced the Zacks Consensus Estimate by 3.6%. It currently carries a Zacks Rank #2.
Masimo has an earnings yield of 3.4% against the industry’s negative yield. MASI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 4.4%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report
Patterson Companies, Inc. (PDCO) : Free Stock Analysis Report
AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
